|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500113224 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-26 10:15:57 |
|
注册时间: Date of Registration: |
2025-11-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
利马前列素片治疗退行性腰椎管狭窄症的前瞻性、观察性研究 |
|
Public title: |
A Prospective, Observational Study of Limaprost Tablets in the Treatment of Degenerative Lumbar Spinal Stenosis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
利马前列素片治疗退行性腰椎管狭窄症的前瞻性、观察性研究 |
|
Scientific title: |
A Prospective, Observational Study of Limaprost Tablets in the Treatment of Degenerative Lumbar Spinal Stenosis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张玉 |
研究负责人: |
张玉 |
|
Applicant: |
Zhang Yu |
Study leader: |
Yu Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 27 65650894 |
研究负责人电话: Study leader's telephone: |
+86 27 85726685 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
whxhzy@163.com |
研究负责人电子邮件: Study leader's E-mail: |
whxhzy@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖北省武汉市江汉区解放大道1277号 |
研究负责人通讯地址: |
湖北省武汉市江汉区解放大道1277号 |
|
Applicant address: |
No. 1277, Jiefang Avenue, Jianghan District, Wuhan City, Hubei Province, P.R. China |
Study leader's address: |
NO.1277 Jiefang Avenue, Wuhan, Hubei Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
华中科技大学同济医学院附属协和医院 |
||
|
Applicant's institution: |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||
|
研究负责人所在单位: |
华中科技大学同济医学院附属协和医院 |
||
|
Affiliation of the Leader: |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2025]伦审字(0983)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
华中科技大学同济医学院附属协和医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Union Hospital of Tongji Medical College Huazhong University of Science and Technology |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-09-18 00:00:00 |
||
|
伦理委员会联系人: |
褚圆圆 |
||
|
Contact Name of the ethic committee: |
Chu YuanYuan |
||
|
伦理委员会联系地址: |
湖北省武汉市江汉区解放大道1277号 |
||
|
Contact Address of the ethic committee: |
NO.1277 Jiefang Avenue, Wuhan, Hubei Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27 85726375 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
994877373@qq.com |
|
研究实施负责(组长)单位: |
华中科技大学同济医学院附属协和医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖北省武汉市江汉区解放大道1277号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
NO.1277 Jiefang Avenue, Wuhan, Hubei Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
利马前列素片治疗退行性 腰椎管狭窄症的前瞻性、观察性研究 |
||||||||||||||||||||||
|
Source(s) of funding: |
A Prospective, Observational Study of Limaprost Tablets in the Treatment of Degenerative Lumbar Spin |
||||||||||||||||||||||
|
Target disease: |
Degenerative lumbar spinal stenosis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
主要目的:比较NSAIDs联合利马前列素片与不联合利马前列素片治疗腰椎管狭窄症的有效性 次要目的: 描述治疗开始后手术相关的情况 比较NSAIDs联合利马前列素片与不联合利马前列素片治疗腰椎管狭窄症的安全性 比较NSAIDs联合利马前列素片与不联合利马前列素片治疗腰椎管狭窄症的药物经济学 评估DLSS患者对主要治疗方案的支付意愿。 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary objective: To compare the effectiveness of NSAIDs combined with limaprost tablets versus NSAIDs alone in the treatment of lumbar spinal stenosis. Secondary objectives:Describe the surgery-related conditions after the start of treatment.Compare the safety of NSAIDs combined with limaprost tablets versus NSAIDs alone in the treatment of lumbar spinal stenosis.Compare the pharmacoeconomics of NSAIDs combined with limaprost tablets versus NSAIDs alone in the treatment of lumbar spinal stenosis.Evaluate the willingness to pay of patients with DLSS for the main treatment regimens. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.诊断为退行性腰椎管狭窄症,性别不限?; 2.直腿抬高试验阴性; 3.存在下肢麻木、疼痛、乏力等症状; 4.开始接受NSAIDs或NSAIDs联合利马前列素片处方治疗DLSS的患者(由研究医生决定); 5.自愿签署知情同意书,愿意接受规范药物治疗; |
||||||||||||||||||||||
|
Inclusion criteria |
1.Diagnosed with degenerative lumbar spinal stenosis (DLSS), regardless of gender; 2. Negative straight leg raise test; 3. Presence of lower extremity symptoms such as numbness, pain, and weakness; 4. Patients who have started receiving treatment for DLSS with non-steroidal anti-inflammatory drugs (NSAIDs) or a combination of NSAIDs and limaprost tablets (as determined by the investigating physician); 5. Voluntarily sign the informed consent form and be willing to receive standardized pharmacotherapy; |
||||||||||||||||||||||
|
排除标准: |
1.有利马前列素片禁忌症的受试者; 2.基线访视前12周内接受过利马前列素片治疗的受试者; 3.患者处于妊娠或哺乳期; 4.诊断为腰椎间盘突出症; 5.正在参与或3个月观察期内计划参与其他干预性临床研究; 6.研究者认为依从性差,或者可能无法完成数据收集的患者; 7.研究者认为可能干扰受试者参加本研究的任何疾病,例如需要急诊手术治疗的疾病、重度认知损害,或其他预计会影响受试者充分完成访视和评估安排的合并症。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Subjects with contraindications to limaprost tablets; 2. Subjects who received limaprost tablet treatment within 12 weeks prior to the baseline visit; 3. Subjects who are pregnant or lactating; 4. Subjects diagnosed with lumbar disc herniation; 5. Subjects who are currently participating in other interventional clinical studies or plan to participate in other interventional clinical studies within the 3-month observation period; 6. Subjects deemed by the investigator to have poor compliance or who may not be able to complete data collection; 7. Subjects with any disease that the investigator deems may interfere with their participation in this study, such as diseases requiring emergency surgery, severe cognitive impairment, or other comorbidities that are expected to affect the subjects' ability to fully complete visit and assessment schedules. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-08-10 00:00:00至 To 2027-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-12-01 00:00:00 至 To 2026-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
no |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC系统数据 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC system data |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |